Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from A highly potent human antibody neutralizing all serotypes of BK polyomavirus. Local targets link to admitted publications; unresolved targets remain external evidence.
Biology of the BKPyV: An Update
10.3390/v9110327 · 2017 · External reference
The Structure of an Infectious Human Polyomavirus and Its Interactions with Cellular Receptors
10.1016/j.str.2018.03.019 · 2018 · External reference
Pathogenicity of BK virus on the urinary system
2020 · External reference
BK polyomavirus: latency, reactivation, diseases and tumorigenesis
10.3389/fcimb.2023.1263983 · 2023 · External reference
Prevalence, Risk Factors, Treatment, and Overall Impact of BK Viremia on Kidney Transplantation
10.1016/j.transproceed.2019.03.035 · 2019 · External reference
The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation
10.1097/tp.0000000000004976 · 2024 · External reference
BK polyomavirus: emerging pathogen
10.1016/j.micinf.2012.02.002 · 2012 · External reference
The human polyomavirus BK (BKPyV): virological background and clinical implications
10.1111/apm.12134 · 2013 · External reference
Co-infection of polyomavirus-BK and cytomegalovirus in renal transplant recipients
10.1097/01.tp.0000165110.78397.93 · 2005 · External reference
Treatment of BK Polyomavirus-Associated Nephropathy in Paediatric Kidney Transplant Recipients: Leflunomide Versus Cidofovir
2024 · External reference
The decade of polyomavirus BK-associated nephropathy: state of affairs
10.1097/tp.0b013e318197c17d · 2009 · External reference
Persistent BK viremia does not increase intermediate-term graft loss but is associated with de novo donor-specific antibodies
10.1681/asn.2014010119 · 2015 · External reference
BK Virus Nephropathy: Histological Evolution by Sequential Pathology
10.1111/ajt.14292 · 2017 · External reference
No clinical benefit of rapid versus gradual tapering of immunosuppression to treat sustained BK virus viremia after kidney transplantation: a single-center experience
10.1111/tri.13392 · 2019 · External reference
Posoleucel in Kidney Transplant Recipients with BK Viremia: Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
10.1681/asn.0000000000000329 · 2024 · External reference
BK polyomavirus in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice
10.1111/ctr.13528 · 2019 · External reference
Intravenous immunoglobulins do not prove beneficial to reduce alloimmunity among kidney transplant recipients with BKV-associated nephropathy
10.1111/tri.13882 · 2021 · External reference
Neutralizing Antibody-Mediated Response and Risk of BK Virus-Associated Nephropathy
10.1681/asn.2017050532 · 2018 · External reference
A Randomized Phase 2 Study of MAU868 vs. Placebo to Treat BK Viremia in Kidney Transplant Recipients
10.1681/asn.20223311s146a · 2022 · External reference
Fast-Track Discovery of SARS-CoV-2-Neutralizing Antibodies from Human B Cells by Direct Functional Screening
10.3390/v16030339 · 2024 · External reference
Unresolved reference
External reference
Nonclinical and clinical characterization of MAU868, a novel human-derived monoclonal neutralizing antibody targeting BK polyomavirus VP1
10.1016/j.ajt.2024.07.002 · 2024 · External reference
Uncovering new families and folds in the natural protein universe
10.1038/s41586-023-06622-3 · 2023 · External reference
A structure-guided mutation in the major capsid protein retargets BK polyomavirus
2013 · External reference
Structural implications of BK polyomavirus sequence variations in the major viral capsid protein Vp1 and large T-antigen: a computational study
10.1128/msphere.00799-23 · 2024 · External reference
Identification of a neutralization epitope in the VP1 capsid protein of SV40
10.1016/j.virol.2008.07.032 · 2008 · External reference
Human Memory B Cells Harbor Diverse Cross-Neutralizing Antibodies against BK and JC Polyomaviruses
10.1016/j.immuni.2019.02.003 · 2019 · External reference
Intravenous immunoglobulin as a preventive strategy against BK virus viremia and BKV-associated nephropathy in kidney transplant recipients-Results from a proof-of-concept study
10.1111/ajt.16233 · 2021 · External reference
Human immunoglobulin variable region gene analysis by single cell RT-PCR
10.1016/s0022-1759(00)00260-x · 2000 · External reference
Predominant autoantibody production by early human B cell precursors
10.1126/science.1086907 · 2003 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Arrangement of L2 within the papillomavirus capsid
10.1128/jvi.02726-07 · 2008 · External reference
Production of papillomavirus-based gene transfer vectors
2007 · External reference
Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients
10.1371/journal.ppat.1002650 · 2012 · External reference
Efficient intracellular assembly of papillomaviral vectors
10.1128/jvi.78.2.751-757.2004 · 2004 · External reference
A simple method of estimating fifty per cent endpoints12
10.1093/oxfordjournals.aje.a118408 · 1938 · External reference
On the Calculation of TCID50 for Quantitation of Virus Infectivity
10.1007/s12250-020-00230-5 · 2021 · External reference
BK polyomavirus‐neutralizing activity of intravenous immunoglobulin products derived from donated blood in Japan
10.1111/voxs.12294 · 2016 · External reference
